WT1 and acute myeloid leukemia: They further demonstrated that, in specific fusion transcript t(8;21)-positive AML, the combined evaluation of the WT1 MRD assay with a threshold of WT1 > 1.8% proved to be a more accurate predictor for relapse [17].